Medivation, Inc. (MDVN): Rick Bierly , CFO (former of Medivation, Inc. sold 10,340 shares on May 5, 2016. The Insider selling transaction was reported by the company on May 9, 2016 to the Securities and Exchange Commission. The shares were sold at $59.98 per share for a total value of $617,917.19 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Mar 16, 2016, Dawn Svoronos (director) sold 6,000 shares at $38.90 per share price.On Mar 7, 2016, David Hung (President and CEO) sold 5,085 shares at $41.10 per share price.Also, On Mar 7, 2016, Mohammad Hirmand (Interim Chief Medical Officer) sold 1,525 shares at $41.10 per share price.On Mar 7, 2016, Rick Bierly (Chief Financial Officer) sold 2,998 shares at $40.00 per share price.
Medivation Inc: On Friday, May 6, 2016 heightened volatility was witnessed in Medivation Inc which led to swings in the share price. The shares opened for trading at $60 and hit $60.99 on the upside , eventually ending the session at $60, with a gain of 1.32% or 0.78 points. The heightened volatility saw the trading volume jump to 38,39,796 shares. The 52-week high of the share price is $66.395 and the company has a market cap of $9,877 M . The 52-week low of the share price is at $26.41.
Company has been under the radar of several Street Analysts.Medivation Inc is Reiterated by Barclays to Overweight and the brokerage firm has raised the Price Target to $ 70 from a previous price target of $48 .The Rating was issued on May 6, 2016.Medivation Inc is Upgraded by Citigroup to Buy. Earlier the firm had a rating of Neutral on the company shares. The Rating was issued on May 6, 2016.Medivation Inc is Reiterated by Maxim Group to Buy and the brokerage firm has raised the Price Target to $ 76 from a previous price target of $47 .The Rating was issued on May 5, 2016.Medivation Inc is Reiterated by Stifel to Buy and the brokerage firm has raised the Price Target to $ 66 from a previous price target of $52 .The Rating was issued on May 2, 2016.Medivation Inc is Reiterated by Jefferies to Hold and the brokerage firm has raised the Price Target to $ 52 from a previous price target of $39 .The Rating was issued on May 2, 2016.
Medivation Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company in collaboration with Astellas Pharma Inc. has one commercial product XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States Europe and other countries worldwide for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company in collaboration with Astellas is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. The Company has licensed exclusive worldwide rights to pidilizumab an immune modulatory anti-Programmed Death-1 (PD-1) monoclonal antibody for all potential indications from CureTech Ltd.